[1]徐锦华a,王慧娟,励 国a,等.老年慢性心力衰竭患者血清SCD-1 和sVEGFR-2 表达水平及其与预后的评估价值研究[J].现代检验医学杂志,2023,38(04):191-195+204.[doi:10.3969/j.issn.1671-7414.2023.04.035]
　XU Jinhuaa,WANG Huijuan,LI Guoa,et al.Study on the Expression Level of Serum SCD-1 and sVEGFR-2 in Elderly Patients with Chronic Heart Failure and Its Prognostic Value[J].Journal of Modern Laboratory Medicine,2023,38(04):191-195+204.[doi:10.3969/j.issn.1671-7414.2023.04.035]
点击复制

老年慢性心力衰竭患者血清SCD-1 和sVEGFR-2 表达水平及其与预后的评估价值研究()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第38卷
期数:
2023年04期
页码:
191-195+204
栏目:
检验与临床
出版日期:
2023-07-15

文章信息/Info

Title:
Study on the Expression Level of Serum SCD-1 and sVEGFR-2 in Elderly Patients with Chronic Heart Failure and Its Prognostic Value
文章编号:
1671-7414（2023）04-191-06
作者:
徐锦华1a; 王慧娟2; 励 国1a; 王 斐1b
（1. 北京市丰台中西医结合医院 a. 急诊科；b. 心内科，北京 100072；2. 首都医科大学附属宣武医院急诊科，北京 100053）
Author(s):
XU Jinhua1a; WANG Huijuan2; LI Guo1a; WANG Fei1b
（1a. Department of Emergency;1b. Department of Cardiology, Beijing Fengtai Integrated Traditional Chinese and Western Medicine Hospital, Beijing 100072, China; 2. Department of Emergency, Xuanwu Hospital Affiliated to Capital Medical University, Beijing 100053，China)
关键词:
多配体蛋白聚糖-1; 可溶性血管内皮生长因子受体-2; 慢性心力衰竭
分类号:
R541.6；R392.11
DOI:
10.3969/j.issn.1671-7414.2023.04.035
文献标志码:
A
摘要:
目的　探讨血清多配体蛋白聚糖-1（serum syndecan-1，SCD-1）和可溶性血管内皮生长因子受体-2（solublevascular endothelial growth factor receptor -2，sVEGFR-2）对老年慢性心力衰竭（chronic heart failure ，CHF）患者预后的预测价值。方法　选择2018 年3 月～ 2021 年10 月北京市丰台中西医结合医院心内科住院部收治的175 例老年CHF患者，检测血清SCD-1 和sVEGFR-2 水平，出院后随访和统计因心力衰竭再次住院和心源性死亡发生情况。多因素Logistic 回归分析老年CHF 患者预后不良的危险因素。受试者工作特征曲线（ROC）分析SDC-1 和sVEGFR-2 预测老年CHF 患者预后不良的价值。结果　177 例老年CHF 患者随访期间失访2 例，最终175 例纳入结果分析。预后不良组血清SCD-1（6.95±1.87 ng/ml）和sVEGFR-2（2.75±0.46 μg/L）水平高于预后良好组（4.21±0.63 ng/ml，1.02±0.35μg/L），差异均有统计学意义（t=14.454，24.465，均P ＜ 0.05）。多因素Logistic 回归分析结果显示NYHA Ⅳ级、高水平B 型脑钠肽、高水平SCD-1，高水平sVEGFR-2 是老年CHF 患者预后不良的危险因素（Waldχ2=8.827, 10.856, 7.594,8.627，均 P ＜ 0.01）。SCD-1 和sVEGFR-2 预测老年CHF 患者预后的曲线下面积为0.700（95%CI：0.626 ～ 0.766）和0.761（95%CI：0.691 ～ 0.822），与BNP［0.804（95%CI：0.737 ～ 0.860）］比较，差异均无统计学意义（z=1.769, 1.123，均P ＞ 0.05）；联合SCD-1，sVEGFR-2 和BNP 预测老年CHF 患者预后的曲线下面积为0.943（95%CI：0.898 ～ 0.973），高于单独SCD-1，sVEGFR-2 和BNP（z=4.586，3.851，3.094，均P ＜ 0.05）。结论　老年CHF 预后不良患者血清SCD-1 和sVEGFR2 水平均显著增高，且与老年CHF 患者预后不良有关，可作为老年CHF 患者预后分析的潜在标志物。
Abstract:
Objective　To investigate the prognostic value of serum syndecan-1 (SCD-1) and soluble vascular endothelial growth factor receptor -2 (sVEGFR-2) in elderly patients with chronic heart failure (CHF). Methods　175 elderly CHF patients admitted to Beijing Fengtai Integrated Traditional Chinese and Western Medicine Hospital from March 2018 to October 2021 were selected. Serum SCD-1 and sVEGFR-2 levels were detected and performed after discharge. Multivariate Logistic regression analysis was used to analyze the risk factors of poor prognosis in elderly patients with CHF. Receiver operating characteristic curve (ROC) was used to analyze the value of SDC-1 and sVEGFR-2 in predicting poor prognosis in elderly patients with CHF. Results　Two of 177 elderly CHF patients were lost during the follow-up period, and 175 were included in the final analysis. The serum SCD-1 (6.95±1.87 ng/ml ) and sVEGFR-2 (2.75±0.46 μg/L) levels were higher than those in the good prognosis group（4.21±0.63 ng/ml，1.02±0.35 μg/L）, and the differences were statistically significant(t=14.454, 24.465, all P< 0.05). The results of multivariate Logistic regression analysis showed that NYHA grade Ⅳ , high level of B-type brain natriuretic peptide, high level of SCD-1 and high level of sVEGFR-2 were risk factors for poor prognosis in elderly patients with CHF （Waldχ2=8.827, 10.856, 7.594, 8.627，all P ＜ 0.01）. The area under the curve of SCD-1 and sVEGFR-2 in predicting the prognosis of elderly CHF patients was 0.700(95%CI：0.626 ～ 0.766) and 0.761(95%CI：0.691 ～ 0.822), which had no significant difference compared with BNP [0.804(95%CI：0.737 ～ 0.860)], the difference was statistically significant （z=1.769,1.123，all P ＞ 0.05）. The area under the curve of combined SCD-1, sVEGFR-2 and BNP in predicting the prognosis of elderly CHF patients was 0.943(95%CI：0.898 ～ 0.973). It was higher than SCD-1, sVEGFR-2 and BNP alone （z=4.586, 3.851, 3.094, all P ＜ 0.05）.Conclusion　Serum levels of SCD-1 and sVEGFR2 are significantly increased in elderly patients with poor prognosis of CHF, which were related to poor prognosis of elderly CHF patients, and can be used as potential markers for prognosis analysis of elderly CHF patients.

参考文献/References:

[1] ZHANG Haohua, ZHANG Nianli, JIANG Wenbin, et al. Clinical significance of the long non-coding RNA NEAT1/miR-129-5p axis in the diagnosis and prognosis for patients with chronic heart failure[J]. Experimental and Therapeutic Medicine, 2021, 21(5): 512.
[2] LING Shuang, XU Jinwen. NETosis as a pathogenic factor for heart failure[J]. Oxidative Medicine and Cellular Longevity, 2021, 2021: 6687096.
[3] YANG Zecheng, CHEN Shuaitong, YING Haoqiang, et al. Targeting syndecan-1: new opportunities in cancer therapy[J]. American Journal of Physiology·Cell Physiology, 2022, 323(1): C29-C45.
[4] MALLICK R, YL?-HERTTUALA S. Therapeutic potential of VEGF-B in coronary heart disease and heart failure: dream or vision[J]. Cells, 2022, 11(24): 4134.
[5] KIVEL? R, HEMANTHAKUMAR K A, VAPARANTA K, et al. Endothelial cells regulate physiological cardiomyocyte growth via VEGFR2-mediated paracrine signaling[J]. Circulation, 2019, 139(22): 2570-2584.
[6] 中华医学会心血管病学分会心力衰竭学组, 中国医师协会心力衰竭专业委员会, 中华心血管病杂志编辑委员会．中国心力衰竭诊断和治疗指南2018[J].中华心力衰竭和心肌病杂志, 2018, 2(4):196-225． Heart Failure Group of Chinses Society of Cardiology of Chinses Medical Association, Chinses Heart Failure Association of Chinses Medical Doctor Association, Editorial Board of Chinses Journar of Cardioloy. Chinese guidelines for the diagnosis and trentment of heart failure 2018 [J]. Chinese Journal of Heart Failure and Cardiomyopathy, 2018, 2(4): 196-225.
[7] 胡小燕, 郑晓, 嵇华夏, 等．血清PCT 与BNP 水平联合检测对慢性阻塞性肺疾病急性加重期并发心力衰竭的临床诊断价值[J]. 现代检验医学杂志, 2021,36(3):128-131, 136. HU Xiaoyan, ZHENG Xiao, JI Huaxia, et al. Clinical diagnostic value of combined detection of serum PCT and BNP levels in patients with acute exacerbation of chronic obstructive pulmonary disease complicated with heart failure[J]. Journal of Modern Laboratory Medicine, 2021, 36(3): 128-131, 136.
[8] ALBAENI A, CHATILA K F, THAKKER R A, et al. In-Hospital outcomes of chronic total occlusion percutaneous coronary interventions in heart failure patients[J]. Current Problems in Cardiology, 2023, 48(2): 101458.
[9] OSUNDOLIRE S, GOLDBERG R J, LAPANE K L. Descriptive epidemiology of chronic obstructive pulmonary disease in US nursing home residents with heart failure[J]. Current Problems in Cardiology, 2023, 48(2): 101484.
[10] GROENEWEGEN A, RUTTEN F H, MOSTERD A, et al. Epidemiology of heart failure[J]. European Journal of Heart Failure, 2020, 22(8): 1342-1356.
[11] HAO Guang, WANG Xin, CHEN Zuo, et al. Prevalence of heart failure and left ventricular dysfunction in China:the China Hypertension Survey, 2012–2015[J]. European Journal of Heart Failure, 2019, 21(11): 1329-1337.
[12] SARMA S, STOLLER D, HENDRIX J, et al. Mechanisms of chronotropic incompetence in heart failure with preserved ejection fraction[J]. Circulation-Heart Failure, 2020, 13(3): e006331.
[13] ZUCHI C, TRITTO I, CARLUCCIO E, et al. Role of endothelial dysfunction in heart failure[J]. Heart Failure Reviews, 2020, 25(1): 21-30.
[14] WERNLY B, FUERNAU G, MASYUK M, et al. Syndecan-1 predicts outcome in patients with STsegment elevation infarction independent from infarctrelated myocardial injury[J]. Scientific Reports, 2019, 9(1): 18367.
[15] CHEN Youquan, HUANG Ming, YAN Yi, et al. Tranilast inhibits angiotensin II-induced myocardial fibrosis through S100A11/ transforming growth factor-β (TGF-β1)/Smad axis[J]. Bioengineered, 2021, 12(1): 8447-8456.
[16] SHARMA P, KAPOOR D, SHUKLA D. Role of heparanase and syndecan-1 in HSV-1 release from infected cells[J]. Viruses, 2022, 14(10): 2156.
[17] RANJBARAN A, NEJABATI H R, GHASEMNEJAD T, et al. Follicular fluid levels of adrenomedullin 2, vascular endothelial growth factor and its soluble receptors are associated with ovarian response during ART cycles[J]. Geburtshilfe Frauenheilkd, 2019, 79(1): 86-93.
[18] WIECZ?R R, RO?? D, WIECZ?R A M, et al. VASCULAR-1 and VASCULAR-2 as a new potential angiogenesis and endothelial dysfunction markers in peripheral arterial disease [J]. Clin Appl Thromb Hemost, 2019, 25:1076029619877440.
[19] HU Guanying, YANG Peng, ZENG Yu, et al. Danggui buxue decoction promotes angiogenesis by upregulation of VEGFR1/2 expressions and downregulation of sVEGFR1/2 expression in myocardial infarction rat[J]. Journal of the Chinese Medical Association , 2018, 81(1): 37-46.
[20] 崔泽岩, 孙倩, 周红霞. 血清糖类抗原125 和N 末端B 型脑钠肽前体对射血分数保留的心力衰竭的诊断与疗效判定及预后的评估价值[J]. 中国医药,2021, 16(4): 503-507． CUI Zeyan, SUN Qian, ZHOU Hongxia. Evaluation of serum carbohydrate antigen 125 and N-terminal probrain natriuretic peptide in diagnosis, efficacy judgment and prognosis of heart failure with preserved ejection fraction [J]. China Medicine, 2021, 16(4): 503-507.

备注/Memo

备注/Memo:
基金项目： 首都卫生发展科研专项项目（首发2020-2-7014）：可溶性血管内皮生长因子及其受体在老年慢性心力衰竭患者血清中的价值研究。
作者简介：徐锦华（1977-），女，本科，副主任医师，研究方向：急诊学，E-mail:xjh123456202211@163.com。
更新日期/Last Update: 2023-07-15